Myocarditis
93
24
30
29
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.2%
2 terminated out of 93 trials
93.5%
+7.0% vs benchmark
4%
4 trials in Phase 3/4
0%
0 of 29 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 29 completed trials
Clinical Trials (93)
Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.
JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors
Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research
Multimodal mAgnetic Resonance imaGIng in Cardiovascular Disease
AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS
Pilot Study Evaluating Somatostatin Receptor's PET Imaging to Detect Inflammatory Phases of Myocarditis
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis
A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.
Contribution of Cardiac MRI in the Early Diagnosis of Myocarditis Induced by Immunotherapy
Mayo AVC Registry and Biobank
Myocardial Injury and Outcomes Following COVID-19 Vaccination (MYOVAX Study)
CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
The Heart Hive - Cardiomyopathy Study
Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support
COVID-19 Vaccine-induced Inflammatory Heart Disease Prevalence Registry
The Application of T1 Mapping in Real-World
Cardiac MRI in Myocarditis and Inflammatory Cardiomyopathy
IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION